Loading
Sentiment · FY2026 Q2
| Analyst | Firm | Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Shlomo Rosenbaum | Stifel | 7 (29%) |
| Elizabeth Anderson | Evercore ISI | 6 (0%) |
| Dave Windley | Jefferies | 5 (0%) |
| Eric Coldwell | Robert W. Baird | 5 (20%) |
| Justin Bowers | Deutsche Bank | 5 (0%) |
| Mike Ryskin | Bank of America | 4 (25%) |
| Jack Meehan | Operon Research | 3 (0%) |
| Jailendra Singh | Truist Securities | 3 (33%) |
| Jeff Garro | Stephens | 2 (0%) |
| Ann Hynes | Mizuho Securities | 2 (50%) |
| Firm | Analysts | Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Stifel | 1 | 7 (29%) |
| Evercore ISI | 1 | 6 (0%) |
| Jefferies | 1 | 5 (0%) |
| Deutsche Bank | 1 |
| 5 (0%) |
| Robert W. Baird | 1 | 5 (20%) |
| Bank of America | 1 | 4 (25%) |
| Leerink Partners | 3 | 4 (0%) |
| Operon Research | 1 | 3 (0%) |
IQVIA exceeded the high end of Q1 2026 guidance with 8.4% reported revenue growth and adjusted EPS of $2.90, up 7.4% year-over-year, as organic growth accelerated driven by AI-enabled commercial solutions innovation. Revenue and EBITDA guidance were reaffirmed while EPS guidance was raised by $0.10 at the midpoint to $12.65-$12.95, reflecting operational execution. R&D Solutions bookings grew double digits year-over-year to $2.5 billion, with low pass-through bookings obscuring strong underlying service fee growth. EBP funding nearly doubled year-over-year as AI disruption concerns paradoxically created demand tailwinds.
Demand | Revenue Growth | Margin | Competitive Dynamics | Cloud & AI | Cost Pressure | Regulation Policy | Pricing | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 5 | 1 | 2 | 1 | 2 | 1 | 1 | |
| 2025Q1 | 5 | 2 | 2 | 2 | 2 | 1 | ||
| 2025Q2 | 7 | 4 | 2 | 4 | 1 | 2 | 1 | |
| 2025Q3 | 4 | 3 | 1 | 2 | 2 | 1 | ||
| 2025Q4 | 2 | 1 | 1 | 4 | 1 | |||
| 2026Q1 | 5 | 2 | 3 | 1 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | |
|---|---|---|---|---|---|---|
| Demand | 5 | 5 | 7 | 4 | 2 | 5 |
| Revenue Growth | 1 | 2 | 4 | 3 | 2 | |
| Margin | 2 | 2 | 2 | 1 | 1 | 3 |
| Competitive Dynamics | 1 | 2 | 4 | 2 | 1 | 1 |
| Cloud & AI | 1 | 2 | 4 | |||
| Cost Pressure | 2 | 2 | ||||
| Regulation Policy | 1 | 1 | 2 | |||
| Pricing | 1 | 1 | 1 | 1 |
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $3.96B | +2.3% | $2.42 | -4.7% | 34.8% | 15.8% | 11.0% | $721M |
| FY2025 Q1 | $3.83B | +2.5% | $1.40 | -10.3% | 33.9% | 13.0% | 6.5% | $426M |
| FY2025 Q2 | $4.02B | +5.3% | $1.54 | -21.8% | 32.9% | 12.6% | 6.6% | $292M |
| FY2025 Q3 | $4.10B | +5.2% | $1.93 | +24.5% | 33.5% | 13.5% | 8.1% | $1.20B |
| FY2025 Q4 | $4.36B | +10.3% | $2.99 | +23.6% | 6.7% | 16.8% | 11.8% | $561M |
| FY2026 Q1 | $4.15B | +8.4% | $1.61 | +15.0% | 32.6% | 12.4% | 6.6% | $491M |
| FY2026 Q2 | $4.37B | +8.7% | $1.53 | -0.6% | 32.9% | 11.6% | 5.9% | $685M |
Management’s own words, often on a non-GAAP, constant-currency, or adjusted basis — so these can differ from the GAAP figures above (e.g. constant-currency revenue growth excludes currency swings).
What IQV and other companies said about each other on FY2026 Q1 earnings calls — extracted verbatim from public transcripts. Mentions from the newest quarter are a Pro feature.
“a couple of the large top 20, for example, were on IQVIA. Okay. Those are going on over to Veeva.”
Veeva flagged competitive takeaways in CRM, with a couple of top-20 pharma customers migrating off IQVIA onto Veeva, a negative read-through for IQVIA's CRM franchise.
“we announced a strategic collaboration with the Duke Clinical Research Institute to advance clinical research in obesity and related cardiometabolic conditions.”
IQVIA formed a strategic collaboration with the Duke Clinical Research Institute for obesity and cardiometabolic trials, creating an integrated academic-CRO model that has already generated a pipeline of opportunities.
“We entered into a strategic, long-term collaboration with Boehringer Ingelheim to transform the global commercial intelligence foundation.”
Boehringer Ingelheim selected IQVIA's Data-as-a-Service plus platform in a strategic long-term collaboration to harmonize global commercial operations across 59 countries, a major commercial-solutions client win.
“Pfizer and IQVIA Holdings Inc. entered into a strategic regional promotion agreement covering selected Pfizer products across 23 countries in Europe.”
Pfizer signed a strategic regional promotion agreement with IQVIA covering selected products across 23 European countries, a commercial-services win that expands IQVIA's partnership with Pfizer.
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
IQV IQVIA | 7 | +8.4% | |
| A Agilent Technologies | 6 | +7.0% | |
| CRL Charles River Laboratories | 4 | +1.2% | |
| DGX Quest Diagnostics | 9 | +9.2% | |
| DHR Danaher Corporation | 7 | +3.7% | |
| IDXX Idexx Laboratories | 8 | +14.3% | |
| LH LabCorp | 8 | +5.8% | |
| MTD Mettler Toledo | 7 | +7.2% | |
| RVTY Revvity | 5 | +7.0% | |
| TMO Thermo Fisher Scientific | 7 | +6.2% | |
| WAT Waters Corporation | 9 | +91.5% |